Leishmaniasis chemotherapy--challenges and opportunities.
about
Management of trypanosomiasis and leishmaniasisPost-Genomics and Vaccine Improvement for LeishmaniaNovel amidines and analogues as promising agents against intracellular parasites: a systematic reviewTargeting UDP-galactopyranose mutases from eukaryotic human pathogensSystematic review of biomarkers to monitor therapeutic response in leishmaniasisA novel function for kojic acid, a secondary metabolite from Aspergillus fungi, as antileishmanial agentCD271+ Mesenchymal Stem Cells as a Possible Infectious Niche for Leishmania infantumThe Potential of Secondary Metabolites from Plants as Drugs or Leads against Protozoan Neglected Diseases-Part III: In-Silico Molecular Docking InvestigationsAdvances in Development of New Treatment for LeishmaniasisNaloxonazine, an Amastigote-Specific Compound, Affects Leishmania Parasites through Modulation of Host-Encoded FunctionsMolecular dynamics reveal binding mode of glutathionylspermidine by trypanothione synthetaseIdentification of semicarbazones, thiosemicarbazones and triazine nitriles as inhibitors of Leishmania mexicana cysteine protease CPBAntileishmanial activity of the estrogen receptor modulator raloxifeneA dual drug sensitive L. major induces protection without lesion in C57BL/6 micePotential of 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinones against Leishmania (L.) infantum: biological activity and structure-activity relationshipsGolgi-located NTPDase1 of Leishmania major is required for lipophosphoglycan elongation and normal lesion development whereas secreted NTPDase2 is dispensable for virulenceDirect comparison of the efficacy and safety of oral treatments with oleylphosphocholine (OlPC) and miltefosine in a mouse model of L. major cutaneous leishmaniasisSterol biosynthesis is required for heat resistance but not extracellular survival in leishmaniaImmucillins ImmA and ImmH Are Effective and Non-toxic in the Treatment of Experimental Visceral LeishmaniasisNeglected tropical diseases in the genomics era: re-evaluating the impact of new drugs and mass drug administrationMonitoring the response of patients with cutaneous leishmaniasis to treatment with pentamidine isethionate by quantitative real-time PCR, and identification of Leishmania parasites not responding to therapy.Functional and genetic evidence that nucleoside transport is highly conserved in Leishmania species: Implications for pyrimidine-based chemotherapy.Potential Challenges of Controlling Leishmaniasis in Sri Lanka at a Disease Outbreak.Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects.Leishmanicidal activities of novel synthetic furoxan and benzofuroxan derivatives.Insilico analysis of hypothetical proteins unveils putative metabolic pathways and essential genes in Leishmania donovani.Visceral leishmaniasis and HIV coinfection in Latin AmericaHigh quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection.Leishmania major methionine sulfoxide reductase A is required for resistance to oxidative stress and efficient replication in macrophages.Target-based vs. phenotypic screenings in Leishmania drug discovery: A marriage of convenience or a dialogue of the deaf?Low resolution structural studies indicate that the activator of Hsp90 ATPase 1 (Aha1) of Leishmania braziliensis has an elongated shape which allows its interaction with both N- and M-domains of Hsp90.An essential type I nitroreductase from Leishmania major can be used to activate leishmanicidal prodrugsEvaluating aziridinyl nitrobenzamide compounds as leishmanicidal prodrugsImmunogenicity evaluation of a rationally designed polytope construct encoding HLA-A*0201 restricted epitopes derived from Leishmania major related proteins in HLA-A2/DR1 transgenic mice: steps toward polytope vaccineNitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis.Antileishmanial and antitrypanosomal activity of the cutaneous secretion of Siphonops annulatusTherapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B.The Heme Transport Capacity of LHR1 Determines the Extent of Virulence in Leishmania amazonensis.In Vitro Susceptibility of Leishmania infantum to Artemisinin Derivatives and Selected Trioxolanes.Chemical and bioassay techniques to authenticate quality of the anti-leishmanial drug miltefosine
P2860
Q24596889-052D149B-2475-462D-ACC8-B3E525038E75Q26752532-1583C41F-8BC9-4DDD-A4ED-8E482E3A7B3AQ26825025-777466BB-1EA0-496C-8668-A3ADD6DDA22AQ26862107-923ED24C-4563-45CE-8DB0-C0F4F97A6040Q26866450-5AA3DDD4-B04C-4433-8D95-F7CC1C69D22CQ27316554-62F66516-77CE-4259-87E9-3CDBA6DBDF06Q27321912-468E28C5-FC68-4AC0-A1ED-9DB715BF81D5Q28066944-0555E826-5041-49E4-A27C-3EF1BDBDF692Q28082097-10CFA91D-5FED-4C9E-994C-1B97C17E4C3FQ28468455-88048FD0-FEB5-43EA-A335-0F4352FD2ED4Q28486718-E7A124B8-4AB0-4DF3-91A5-FC928181CD17Q28534433-AC576B23-CC7C-4D9E-B23E-D2FA87F71065Q28538576-48060696-01D5-4746-B4E4-EDDB5AF6AD60Q28539173-A4A7A749-4769-48EE-A903-E0AF75F42D69Q28542652-7C2678FD-36B3-49EC-BF37-CC4B14447127Q28542765-4D61CF6D-7D84-41F7-A9B9-B3EA39D101FAQ28542936-C3FD5B84-902F-4E2F-9275-2585B070F7E7Q28544093-D0431F19-C6D3-48D6-BB02-C0AE3E40BB7BQ28551736-83FA18FA-9EDE-433A-8301-38D3A7C30199Q28602660-B451E4D9-1371-4400-878C-8EC52EF52FCCQ29353558-EE15D82B-F336-4C54-98E7-44DC5455E602Q33610259-30F08C6F-E783-4FD0-8CD8-5E88C0F3C2E7Q33786761-7290D13F-1CD7-4C3E-B535-B2AF29E934C6Q34054948-45D4DE7D-C6FB-4C07-96ED-72044010EC7DQ34058373-FAE6AA96-D50E-40C3-AD97-4CE32C20198AQ34087781-6610DAFF-1A58-4EE0-926A-D6F53279F360Q34214794-9DD0C906-40B7-4EA4-8556-9E9B0E31687AQ34310410-20B9F58A-B297-4ABE-83BA-D89F3696BE44Q34598358-D649A346-5659-4D32-A879-4582F49831CEQ34705805-E9683026-B198-4A5E-AC52-D4367D31EEE7Q34796079-862539EA-F991-4983-AB4A-AD15B2BF601DQ34942136-3074D03B-BC45-49A9-972E-D35AAEBFD7D6Q35027309-AAD7C49F-1361-4502-A763-98AC8F4BAA61Q35326248-D145C20F-D8E2-4624-8499-184DF6FBCA9CQ35412114-FEDFFC62-3595-4615-9340-3E8A9391215FQ35413035-65A00579-FE29-42A8-9FD0-02FF8B60929AQ35605511-98DD7365-8032-4CCE-8958-B5BFB329EAC6Q35636822-2CBA36DF-8E8E-49E2-8B51-6EBA954CEBD8Q35642768-A69EB46D-3E76-4B66-91FA-C8243B163A22Q35681782-CD23C6F7-9A66-449C-9B04-314508D2F639
P2860
Leishmaniasis chemotherapy--challenges and opportunities.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Leishmaniasis chemotherapy--challenges and opportunities.
@en
Leishmaniasis chemotherapy--challenges and opportunities.
@nl
type
label
Leishmaniasis chemotherapy--challenges and opportunities.
@en
Leishmaniasis chemotherapy--challenges and opportunities.
@nl
prefLabel
Leishmaniasis chemotherapy--challenges and opportunities.
@en
Leishmaniasis chemotherapy--challenges and opportunities.
@nl
P1476
Leishmaniasis chemotherapy--challenges and opportunities.
@en
P2093
P304
P356
10.1111/J.1469-0691.2011.03630.X
P577
2011-10-01T00:00:00Z